Member Info for wozzer70

Consolidation & evidence:

Trigger: A few weeks/months of Guident trading and newsflow (contracts, coverage, liquidity).

If Guident holds or improves on IPO levels, the argument that TEK’s discount is purely structural (small cap, holding‑company) gets stronger.

That’s when a more durable re‑rate can set in, as opposed to a one‑day spike.

If Guident can hold or build on its IPO price over time, it gives the market confidence that TEK’s SOTP isn’t a ‘one‑day wonder’, and any sustained narrowing of the discount can be justified, not just momentum.

IPO pricing & first trading days:

Trigger: Guident prices the IPO and starts trading on NASDAQ.

If it prices and trades within or above the range on decent volume, TEK’s look‑through Guident stake stops being theoretical.

This is where you can reasonably argue for TEK to move closer to some fraction of SALT + GDNT + GNIP, not just SALT.

Post‑IPO, TEK should logically trend towards reflecting a chunk of the combined SALT + GDNT + GNIP value, rather than MicroSalt alone. The exact level depends on where GDNT trades and what discount the market applies

Trigger: Guident S‑1 is declared effective and the deal is officially live.

Market reaction: relief rally if investors see this as removing a big execution risk.

Plausible dynamic: TEK starts to move from “priced just on SALT” towards “SALT + some Guident”, but still with a big discount.

Effectiveness takes Guident from ‘if’ to ‘when’; I’d expect some narrowing of the extreme discount but still a meaningful gap while the market waits to see actual trading

IPO valuation = price and shares in issue - focusing on price alone is incomplete.

Until final pricing/effectiveness is confirmed, the only verifiable reference points are:

• latest filed price range

• share count in the prospectus

• TEK’s disclosed % holding

Everything else is speculation.

The key shift isn’t whether it’s $4 or $8 - it’s when Guident moves from a filed range to a live market valuation. That’s the point at which TEK’s discount can be assessed against observable pricing, not assumptions.

The wait for clarity is now almost upon us — not long now.

Fair point on Guident pricing - the latest filings indicate a lower price range with a higher share count vs earlier assumptions.

My post was using a prior mid-point for illustration, but the exact IPO valuation will ultimately be set at pricing.

The key point remains the same for me:

➡️ moving from internal/book value to a live market valuation is the main catalyst for closing the current discount.

Medium‑term framework only – no timeframes implied, not a forecast.

1) Recognition Phase

Market starts to align TEK’s share price with MicroSalt’s look‑through value covering most of the current market cap.

2) Validation Phase

Further Guident filings / IPO visibility reduce uncertainty around the proposed NASDAQ listing.

3) Catalyst Phase

Guident IPO effectiveness + listing → a live market valuation is introduced for TEK’s Guident stake.

4) Re‑rating Phase

The discount between TEK’s share price and its underlying SOTP can begin to narrow as the market prices in clearer asset values.

5) Expansion Phase (conditional)

If Guident trades strongly post‑IPO, the SOTP itself increases, creating room for further upside beyond any initial discount‑closing move

If Guident achieves a stronger market reception post‑listing (for example, trading in the $8–$10+ range versus the current filing mid‑point range), this would imply:

A materially higher valuation for TEK’s ~70% stake in Guident.

A potential uplift to the overall SOTP beyond the current ~£43m core estimate.

👉 In that scenario, the current discount between TEK’s share price and its look‑through asset value would initially widen further before any re‑rating

(Approx. prices as at 18 March 2026)

Core Math

TEK share price: ~7.7p (approx.)

TEK market cap: ~£19.7m (≈$25.1m)

Live Asset Backing

MicroSalt (SALT) – 62.9% stake

Price: 53.2p (approx.)

Implied mkt cap: ~£29.8m

TEK stake: ≈£18.7m (≈$23.8m)

Guident (GDNT) – ~70% stake (IPO pending)

Using latest S‑1/FWP mid‑point c. $8.80 per share and ~2.9m shares:

TEK stake: ≈$26m (≈£20.5m)

​

Status: FWP filed, effectiveness the next key NASDAQ step.

​

GenIP (GNIP) – 63% stake

Price: 9.3p (approx.)

Implied mkt cap: ~£7.1m

​

TEK stake: ≈£4.5m (≈$5.7m)

Conservative Adjustments

Belluscura: assumed £0 (post Chapter 7 at Belluscura LLC).

​

Lucyd / Innovative Eyewear: excluded to stay conservative.

Simple View

Core asset value (SALT + GDNT + GNIP): ≈£43.7m (≈$55.6m)

TEK market cap: ≈£19.7m (≈$25.1m)

👉 TEK is trading at roughly a 55% discount to these three core assets alone.

Key Takeaway

At current prices, the market is largely pricing in MicroSalt, while applying a significant discount to:

Guident (IPO pending)

GenIP

Remaining portfolio assets

What Changes This

Guident moving from:

IPO process → live NASDAQ valuation.

That shift typically reduces uncertainty and can narrow holding‑company discounts when the underlying asset gets a clear market price.

​

Bottom Line

This is not based on forward projections.

It reflects:

Live market values + IPO pricing benchmarks vs current TEK valuation.

And the gap remains material.

At this point, there are only two realistic paths:

🟢 Path 1 – EFFECTIVENESS Next (Most Likely)

SEC comments are largely resolved

Minor tweaks already handled in last amendment

Company proceeds to effectiveness

👉 This fits what we’re seeing now.

🟡 Path 2 – One Final “Light” Amendment

Small clarifications

Legal tidy-ups

No structural changes

👉 If this happens, it’s usually:

Quick… and then straight to EFFECT

Guident has now filed a Free Writing Prospectus (FWP), which is a key step in the IPO process.

This is not another standard amendment — it signals that the company is now actively presenting its investment case to institutions ahead of effectiveness.

Key points: • $15M raise at $4–$5 range

• 3.33M shares offered

• 180-day lock-up in place

• Majority of proceeds allocated to growth (sales & expansion)

• Patent portfolio highlighted (~$32M valuation)

• Existing deployments in Florida supporting commercial progress

Timeline now progressing: S-1 → Amendments → FWP (marketing) → EFFECT → IPO

This marks a shift from regulatory process to investor engagement.

With the structure now defined and marketing underway, the next key milestone is SEC effectiveness.

As always, the market will price this in stages.

https://www.sec.gov/Archives/edgar/data/2066926/000182912626002372/guidentcorp_fwp.htm

Following the latest S-1/A from , it’s worth stepping back and looking at both the IPO process and current chart position.

IPO Process (Progression):

S-1 Filed ➡️ Amendments (ongoing) ➡️ SEC Effectiveness ➡️ Pricing ➡️ NASDAQ Trading

We’ve now clearly moved through multiple amendment stages, with updated financials included. That suggests the process is progressing rather than stalled.

Technical Position – :

Strong support holding ~7p

Compression within a wedge structure

Recent move off support with increased volume

What matters next:

The key trigger remains SEC effectiveness. Until then, price may continue to build within the current range.

Summary:

Process advancing + support holding = setup building.

Next step is confirmation, not speculation

Price action on Tekcapital plc is currently sitting at a very interesting point technically.

On the monthly view, TEK appears to be forming a descending wedge, with price compressing between lower highs and a well-defined support zone around 7p. This type of structure often precedes a breakout once pressure builds.

Support in the 6–7p region has now been tested multiple times and continues to hold, suggesting sellers are being absorbed rather than price breaking down.

There is also a visible price gap from earlier movement, which may act as an area of interest as momentum returns.

Looking at the broader chart:

Historical support: ~6–7p

Near-term resistance: ~8–10p

Clustered resistance zones: ~10–15p

A break above the wedge and through the 8–10p region would likely signal a shift in sentiment, with scope to move through the lower resistance bands relatively quickly.

With the ongoing progress of Guident Corp. towards a potential NASDAQ IPO, this technical setup is worth watching closely as we move into a key period.

As always, charts are only one part of the picture, but the current structure suggests compression rather than capitulation.

Charts

https://docs.google.com/document/d/12AXekfMiPgzH3NpokvrMCCTe8l0QNIoxjFLNspCK61w/edit?usp=drivesdk

The market is still asleep, but Tekcapital’s portfolio is quietly building momentum. With Guident approaching its NASDAQ debut, here’s a high-level roadmap for what could unfold:

Stage 0 – Current Base (7.6–8p)

Tek sits at historical support, bears are loud, but the NAV discount is fully priced in. Early RNSs like MicroSalt validate the ecosystem quietly.

Stage 1 – Pre-IPO Anticipation (8–10p)

Whispers of Guident effectiveness or SEC progress start shifting sentiment. Shorts tighten, early bulls accumulate.

Stage 2 – IPO Effectiveness / Filing Confirmation (10–13p)

The market begins to recognise a liquid, transparent portfolio. Private asset discount starts to unwind.

Stage 3 – Guident Goes Live on NASDAQ (15–20p+)

The first ticker falls, portfolio liquidity becomes visible. Institutional attention rises. NAV discount narrative collapses.

Stage 4 – Post-IPO Flow & Dividend Potential (20–30p+)

Lock-ups expire, monetisation of MicroSalt, GenIP, and Lucyd starts feeding the parent. Tek transforms into a self-funding growth platform.

Stage 5 – Full Portfolio Recognition (NAV parity+)

All assets trading, full NAV visibility, Tek now a compounder. Shorts fully marginalized; rerate complete.

Bottom line: Every IPO, every listing, every monetisation step is another brick in the bridge from 7–8p to a fully recognised, liquid, growth portfolio. The market will catch up - it’s only a matter of time.

Onwards and upwards 👊

To the Bears: The Guident Delay Was Never What You Thought 🥊

Many here ran with the “failed effectiveness” narrative on 17th Feb. Let’s set the record straight: the SEC never blocked the IPO, they simply required full-year 2025 audited financials—now delivered in S-1/A7.

Here’s the reality:

Administrative, not structural: The delay was a paperwork hurdle, not a sign the IPO or underlying assets were in trouble.

Numbers now solid: 2025 audited financials included, clearing the way for Nasdaq effectiveness.

TEK NAV unlock imminent: All the “stuck assets” talk? Pure bear noise. The market has heavily discounted TEK because Guident’s IPO wasn’t live. That unlock is now weeks away.

Timing perfect: Mid-March to early April is now the clean window for listing, with realistic $4.00–$5.00 pricing aimed at institutions.

This isn’t a drag- it’s the final step before the catalyst everyone’s been waiting for. Bears doubted, ignored the fundamentals, and the facts now speak for themselves.

TEK shareholders, get ready- this is what clarity looks like.

The market was spooked by the “failed effectiveness” on 17th Feb, but the latest S-1/A7 filing shows exactly what happened: the SEC required full-year 2025 audited financials before granting approval. That step is now complete.

Key Takeaways:

Financials Reset: 2025 audited numbers are now included, removing the stale-data issue that held up the IPO.

Timing Window: With these financials, the IPO has a clean runway until mid-May. Mid-March to early April now looks ideal.

Pricing Discipline: The $4.00–$5.00 per share range signals realistic pricing aimed at institutional support, not vanity valuations.

Unlocking NAV: TEK’s current NAV is heavily discounted because the market has treated these assets as “stuck.” A successful Nasdaq IPO will release that latent value directly.

This isn’t a delay - it’s the final administrative step. Once effective, Guident is ready to go live, and TEK shareholders stand to see the crystallization of long-anticipated value

Scenario 1: “Ready but Backlogged”

Status: Guident already has its audited financials prepared; S-1 is essentially complete.

Reason for delay: SEC backlog (hundreds of IPOs in the queue) or minor administrative timing issues (like the short US government shutdown).

Next steps:

SEC assigns review time as filings work through backlog.

Minor amendments might be needed (e.g., audit refresh if required).

Effectiveness declaration ➡️ IPO goes live.

Timeline: Usually a few weeks to 1–2 months depending on SEC workload.

Key point: The heavy lifting is already done; it’s mostly a waiting game dictated by external bottlenecks.

Scenario 2: “Full Cycle Refresh”

Status: S-1 may need a full financial refresh because timing crossed fiscal year boundaries, or SEC requested additional disclosures.

Reason for delay: Not ready to go live without updated financials, amended filings, or audit adjustments.

Next steps:

Prepare new audited financials.

File amended S-1 with SEC.

Respond to SEC comments (could be one or more rounds).

SEC declares Effectiveness ➡️ IPO goes live.

Timeline: Typically 4–8 weeks or longer if multiple comment rounds are needed.

Key point: This is the slower path—everything must go through the SEC’s full review again, even if the company is otherwise “ready.”

✅ Bottom line:

Scenario 1 = minimal delay, mostly external.

Scenario 2 = longer delay, internal work plus full SEC review.

I personally would lean towards scenario one, starting from the 17th February 2026.

Not long now, patience pays 🎯

For those asking why Guident didn’t IPO before 17 February, this is simply how the process works.

If effectiveness isn’t granted before financials age out, the filing must be refreshed:

• Updated audited financials

• Auditor sign-off

• Legal updates to the S-1

• SEC comment review

• New EFFECT filing

This is standard IPO procedure, not a cancellation.

Given the SEC backlog and the short government shutdown period, delays were expected across the market.

The Guident IPO process hasn't stopped - it simply reset to the next effectiveness window.

MicroSalt, Lucyd and GenIP already have market valuations.

Guident remains the final major asset awaiting price discovery.

Once Guident has a NASDAQ valuation, most of Tekcapital’s portfolio will have visible market references.

That’s typically when holding company discounts begin to narrow.

Anyone wanting to understand Tekcapital should focus on the filings, portfolio valuations and monetisation strategy.

The framework becomes much clearer when you look at the full portfolio rather than individual pieces in isolation.

Tekcapital was never designed to be a dividend income vehicle in the early stages.

The model is build ➡️ list ➡️ monetise ➡️ recycle capital.

MicroSalt, Lucyd and GenIP already have public market valuations.

Those listings are part of the monetisation process, not the end of it.

Guident is the largest remaining private asset, which is why the market is focused on it.

Cash generation at the parent level comes from disposals, loan repayments and strategic sales - exactly how the model is designed to work.

That’s how Tekcapital has grown NAV from roughly $33m in 2020 to over $77m

Why Guident Hasn't IPO'd Yet

Guident filed its S-1 and progressed through SEC review.

IPO timing shifted and the process extended long enough that the financials require an audit refresh before effectiveness.

That is standard for US IPOs where the review period runs longer than expected.

There is no public filing stating the IPO failed or was undersubscribed.

Once the updated financials are filed and declared effective, the market will be updated.